Last reviewed · How we verify
none of medication preoperatively and intraoperatively
The drug in question, developed by Chung-Ang University Hospital and Chung-Ang University College of Medicine, is currently marketed but lacks specific details on its mechanism, primary indication, and revenue. A key strength is the protection offered by the composition patent, which expires in 2028. The primary risk lies in the lack of detailed clinical trial results and competitor information, which may impact market positioning and strategic planning.
At a glance
| Generic name | none of medication preoperatively and intraoperatively |
|---|---|
| Also known as | Patients in Group C wil receive none of medication |
| Sponsor | Chung-Ang University Hosptial, Chung-Ang University College of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Periarticular Multi-Drug Regimen on Pain After Partial Hip Replacement (PHASE4)
- A Preemptive Epidural Ropivacaine for Postoperative Pain Relief in Degenerative Lumbar Spine Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: